Fig. 3: Anti-SARS-CoV-2 IgG binding titer kinetics.

NHP (n = 8/group) were challenged with 2 × 10⁵ TCID₅₀ Delta and simultaneously treated with RBD-62 (green circles) or PBS (gray circles). IgG binding titers were measured to wildtype, Delta and BA.1 RBD in a serum, b BAL and c nasal wash 1 month prior to challenge (pre-challenge) and on days 2, 4, 7, 9 and 14 post challenge. Serum was initially diluted 1:100 and then serially diluted 1:4. BAL and NW samples were initially diluted 1:5 and then serially diluted 1:5. Circles, boxes and horizontal lines represent individual animals, interquartile range and median, respectively, while minima and maxima are denoted at whisker termini. P values annotated on plots can be used to assess the statistical significance of a drug-specific treatment effect (difference between RBD-62 and control groups), based on two-sided generalized estimating equation (GEE) modeling, which included titers across all post challenge timepoints. No adjustments were made for multiple comparisons. NS denotes that the indicated comparison was not significant, with P > 0.05. See also Supplementary Table 4 for complete statistical analyses. Source data are provided as a Source Data file.